PUNE, India, November 22, 2016 /PRNewswire/ -- According to a new market research report " Coagulation/Hemostasis Analyzer Market by Product (Clinical Laboratory & PoCT Analyzers), Consumables, Test (PT, Fibrinogen, APTT, ACT, D Dimer, Platelet Function), Technology (Mechanical, Optical, Electrochemical), End User (PoCT) - Forecast to 2021" published by MarketsandMarkets, the market is projected to reach USD 4.84 Billion by 2021 from USD 2.98 Billion in 2016, at a CAGR of 10.2% from 2016 to 2021. (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ) Browse 96 market data Tables and 57 Figures spread through 167 Pages and in-depth TOC on"Coagulation/Hemostasis Analyzer Markethttp://www.marketsandmarkets.com/Market-Reports/hemostasis-coagulation-analyzer-market-197226392.htmlEarly buyers will receive 10% customization on this report. This report provides a detailed overview of the major drivers, restraints, challenges, opportunities and strategies impacting the Coagulation Analyzers Market along with the estimates and forecasts of the revenue and market share analysis. The major factor driving the growth of this market are increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide. The report segments this market based on product, test, technology, end-users, and regions. Among the products, the clinical laboratory analyzers are expected to account for the largest share of the market. The high growth of clinical laboratory analyzers can be attributed increasing rental agreements and increasing prevalence of blood related diseases worldwide. Speak to our research experts:http://www.marketsandmarkets.com/speaktoanalyst.asp?id=197226392 On the basis of type of test, the Coagulation Analyzers Market is segmented into nine major test segments, namely, prothrombin time testing, fibrinogen testing, ACT, aPTT, d dimer testing, platelet function test, anti-factor Xa test, heparin & protamine dose response test for ACT and other coagulation tests. The prothrombin time testing is the largest test segment of this market, owing to the increasing incidence of cardiovascular and blood related diseases.